
|Articles|January 2, 2006
Endo provides more info on oxymorphone ER and IR tablets
Advertisement
Endo Pharmaceuticals has responded to the FDA's request for more information on the company's application for the investigational painkillers oxymorphone extended-release (ER) and immediate-release (IR) tablets. The FDA requested additional clinical trials to further confirm the safety and efficacy of the products after issuing approval letters in October 2003. If its product is approved, Endo said it's prepared to launch oxymorphone in the second half of 2006.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Cigna to Remedy Years of Unfair Business Practices with Patients and Pharmacies
2
FDA Reaffirms Strict Regulations Amid GLP-1 Compounding Concerns
3
GLP-1 Receptor Agonists Show Potential as Tools Against Chronic Inflammation in Diabetes
4
Tryptyr Increases Tear Production in Dry Eye Disease
5




































